Evidence map›Paper›PMID 36685168›Full record

ArticleCancer research communications2023

Combination Chemotherapy of Multidrug-resistant Early-stage Colon Cancer: Determining Optimal Dose Schedules by High-performance Computer Simulation.

Chase Cockrell, David E Axelrod

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Chase CockrellDepartment of Surgery, University of Vermont College of Medicine, Burlington, VT 05405, USA.ORCID 0000-0003-3224-7617
David E AxelrodDepartment of Genetics, and Cancer Institute of New Jersey, Rutgers University, Piscataway, NJ 08854-8082, USA.ORCID 0000-0002-0912-3870
Rutgers, The State University of New Jersey · USUniversity of Vermont · US

Funding

TRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Tracie Saunders · 1997 to 2026
$94.5M
Agent-based Models to address the Crisis of Reproducibility and Precision MedicineU01EB025825 · NIBIB · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI AN, GARY, FAISSOL, DANIEL M · 2018 to 2021
$2.3M
NCI NIH HHS P30 CA072720NIBIB NIH HHS U01 EB025825
6 · The paper itself

Abstract

The goal of this project was to utilize mechanistic simulation to demonstrate a methodology that could determine drug combination dose schedules and dose intensities that would be most effective in eliminating multidrug resistant cancer cells in early-stage colon cancer. An agent-based model of cell dynamics in human colon crypts was calibrated using measurements of human biopsy specimens. Mutant cancer cells were simulated as cells that were resistant to each of two drugs when the drugs were used separately. The drugs, 5-flurouracil and sulindac, have different mechanisms of action. An artificial neural network was used to generate nearly two hundred thousand two-drug dose schedules. A high-performance computer simulated each dose schedule as a

Indexed as

Colonic NeoplasmsDrug Resistance, MultipleAntineoplastic Combined Chemotherapy ProtocolsComputer SimulationDrug Resistance, NeoplasmHumansAntineoplastic agentsColorectal neoplasmComputer simulationDrug administration scheduleDrug resistant neoplasm

Identifiers

PMID36685168
PMCPMC9851383
OpenAlexW4312069724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.